Biomimesys
HCS Pharma is delighted to help Vidac Pharma in the fight against cancer
Rehovot (Israel) London (UK) and Lille (France) Vidac Pharma is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. Vidac Pharma and HCS Pharma announce cooperative agreement on acceleration of pre-clinical assays for Vidac Pharma Read more…
Biomimesys
Advantages of 3D Cell Culture in Immuno-Oncology
In recent years, 3D cell culture has emerged as a promising approach to studying the immune system and its interactions with cancer cells. Indeed, 3D cell culture mimics better the natural architecture of tissues and provides a more physiologically relevant models for drug discovery. One of the major advantages of Read more…
biomimesys_oncology
The importance of 3D culture for the study of driver oncogenes
A driver oncogene is a gene that, when activated by mutation or altered in expression, contributes importantly to the development and progression of cancer. In other words, alteration of this kind of genes lead to the transformation of a normal cell into a cancerous cell by activating signaling pathways involved Read more…
Biomimesys
We asked to ChatGPT what BIOMIMESYS technology can bring you to immuno-oncology
… And it is right ! “Biomimesys technology can bring several advantages in immuno-oncology by providing a more physiologically relevant 3D cell culture model for research. This technology uses a bioinspired extracellular matrix to create a three-dimensional environment that more closely resembles the natural cellular environment. In immuno-oncology, 2D cell Read more…
Biomimesys
Development of personalized therapeutic targeting in lung cancer using 3D model with BIOMIMESYS® thanks to Plan France Relance and Region Hauts-de-France
It is with great pleasure that we announce the reinforcement of our collaboration about lung cancer between HCS Pharma and TARGET team of the OncoLille Institute (Team “Efficacy and resistance to anti-tumor targeted therapies”, CANTHER UMR9020, Lille, France). Initially supported by Région Hauts-de-France, this project has been initiated in spring Read more…
Biomimesys
Meet HCS PHARMA at Forum Labo!
We will be pleased to meet you in Paris from the 28th to 30th of March. Join Thierry DE CATHEU Business Director, Mathieu LAOUENAN Chief Commercial Officer, Paul COUVREUR and Rita HIEN Junior Business Developpers. Meryl Roudaut, our Project leader in metabolic tissues, and our Project director Elodie VANDENHAUTE will Read more…
Biomimesys
It is Blue March for colon cancer testing!
Why is testing important? One million cases of colon cancer are diagnosed each year around the world. Colorectal cancer develops slowly. The tumor, called polyp, appears on the inner wall of the colon and rectum. The evolution of a polyp into cancer can last about ten years. The test can Read more…
Biomimesys
Three projects for HCS Pharma with ONCOLille Institute thanks to Plan France Relance and Région Hauts-de-France
The beginning of 2023 is tremendous for HCS Pharma in terms of new oncology-related collaborative R&D projects, with three of them accepted and granted by ANR (Agence Nationale pour la Recherche) through the Plan France Relance, and by the Région Hauts-de-France through STIMuLE plan. It has been announced in a Read more…
Biomimesys
What are the in vitro alternatives to animal testing in breast cancer research?
2.2 million cases of breast cancer were identified in 2020 by the WHO. This cancer is the first cause of cancer in women. It develops in the glandular lobes or milk ducts. Five subtypes of breast cancer have been defined but their origin is not yet determined. The heterogeneity of Read more…
Biomimesys
New 3D in vitro model of dysbiosis-induced colon cancer thanks to France Relance Plan
It is a pleasure to announce that HCS Pharma has a new collaborative project dealing with Inflammasome et ion channels Team of OncoLille (PHYCELL Lab, INSERM U1003) in the frame of colon cancer, thanks to France Relance plan and Region Hauts-de-France. This project has started in October 2022 for 2 Read more…
Biomimesys
Feedback to the first OncoLille Days Congress
The first edition of OncoLille Days congress took place from November 2th to 4th, 2022 in Lille. All 3 days were very rich in interesting presentations about interdisciplinary research in oncology, including biology, mathematics, human sciences, etc. Our project leader Véronique De Conto was pleased to present her poster about Read more…
Biomimesys
Poster : Development of personalized therapeutic targeting in lung cancer with METex14 mutation
Abstract: Lung cancer is one of the most frequent cancers in the world with a high mortality rate. The discovery of oncogenic alterations in these cancers allowed the development of targeted therapies against several receptor tyrosine kinases (RTK) including EGFR, ALK or MET and contributed to improve the prognosis of Read more…
Biomimesys
Poster – Including the matricial tumoral microenvironment in 3D in vitro models by using a Hyaluronic-Acid-based hydroscaffold™
Abstract: In oncology, 97% of drug candidates fail in clinical trials. This highlights a lack of relevance of preclinical models used upstream. Indeed, human in vitro models don’t consider the Tumoral Extracellular Matrix (TECM). However, more and more studies demonstrate that ECM composition and stiffness are modified in tumors and Read more…
Biomimesys
Meet us in OncoLille Days 2022 where we present a poster about matricial tumoral microenvironment in 3D in vitro models
We are pleased to participate in the first OncoLille Days congress from November 2th to 4th, 2022. Inaugurated on October 12th, 2022, OncoLille Institute aims at developing an interdisciplinary research in oncology, including biology, physics, microtechnologies, chemistry, mathematics, bioinformatics, statisitcs, health technologies and social and human sciences. HCS Pharma collaborates Read more…
Biomimesys
Using BIOMIMESYS® Oncology in cancer research, results and future possibilities
Solid tumors are associated with a modified microenvironment, in particular an enhanced collagen content and increased stiffness at the level of the extracellular matrix (ECM). These ECM changes are now recognized as important drivers of cancer initiation, progression, and propagation, and also impact the responses of cancerous cells to treatments. Read more…
Biomimesys
Webinar “Using BIOMIMESYS® Oncology in cancer research, results and future possibilities” June 28 & 30
When Tuesday, June 28, 2022 – 9AM (CEST) / 3PM (CST) / 4PM (JST) / 3AM (EST) Thursday, June 30, 2022 – 1PM (CEST) / 7PM (CST) / 8PM (JST) / 7AM (EST) Where Online, using zoom.us and live on Youtube What Solid tumors are associated with a modified microenvironment, Read more…
Biomimesys
Extracellular Matrix Modifications in Lung Cancer Initiation, Progression and Propagation
The Extracellular Matrix (ECM) is a major component of all the organs. This dynamic structure is involved not only in cell adhesion, but also in physiological processes, including cell differentiation, migration, and maturation, tissue homeostasis, biochemical signal retention and mediation, and growth factors’ retention. Moreover, the ECM can be abnormally Read more…
Biomimesys
Matrix stiffness: a key feature in cancer progression
Increased ExtraCellular Matrix (ECM) stiffness is a common process in many cancers (Pickup et al, 2014). This process influences the behaviour of cancer cells in the tumour microenvironment. The accumulation of ECM in the stroma is mainly due to a high production of ECM molecules by TGF-β(Transforming Growth Factor-beta) -stimulated Read more…
Biomimesys
On the importance of the physical features of cancer
Historically, cancer has been described as originating from modified cells, because of mutations impacting their growth, their differentiation and their way (not) to die. Now, it is widely acknowledged that the microenvironment surrounding these cells is involved in cancer initiation and progression. As explained in the article by Nia Munn Read more…
Biomimesys
Extracellular matrix modifications are involved in cancer initiation, progression and propagation
The extracellular matrix (ECM) is the non-cellular component of tissue. Its is mainly composed of structural and adhesion molecules, such as hyaluronic acid, collagene, proteoglycans, fibronectin, elastin, although its specific composition and structure vary between different tissues. It is a dynamic structure, which is involved not only in the cell Read more…
Biomimesys
Applications for 3D in vitro models with BIOMIMESYS® Oncology
Solid tumors are associated with a modified microenvironment, in particular an enhanced collagen content and increased stiffness at the level of the extracellular matrix (ECM). These ECM changes are now recognized as important drivers of cancer initiation and progression, and also impact the responses of cancerous cells to treatments. Made Read more…
Biomimesys
The extracellular matrix modification in pulmonary fibrosis
The lung is a vital organ which allows gas exchanges between the external environment and the body. These gas exchanges take place in alveoli, formed by 2 cell types : pneumocytes I and II (Martinez et al., 2017). The alveolar wall is supported by a basal membrane mainly composed of collagen Read more…